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Synaptic dysfunction occurs early in the progression of Alzheimer’s disease (AD) and correlates with memory
decline. There is emerging evidence that deregulation of Erythropoietin-producing hepatocellular (Eph) receptor
tyrosine kinases (RTK) signaling contributes to the aberrant synaptic functions associated with neurodegeneration.
The Eph receptor A4 is highly expressed in human adult hippocampal brain tissue and was previously linked to
cognitive impairment in a transgenic mouse model for AD. Whether EphA4 levels are altered in AD brain remains
elusive. Therefore we investigated the protein levels and localization of EphA4 in human hippocampus derived from
AD (n = 29) as well as non-demented control cases (n = 19).
The total EphA4 protein levels were not changed in AD patients compared to control cases. However,
immunohistochemical localization of EphA4 revealed an altered distribution in AD compared to control
hippocampus. EphA4 immunoreactivity was observed in plaque-like structures in AD cases. Double-labelling with
phosphorylated tau and amyloid beta indicates that EphA4 co-localizes with neuritic plaques in AD. This altered
distribution pattern was observed at early stages (Braak stage II) and correlates with the hallmarks of AD pathology
suggesting a reduced availability of EphA4 that is likely to contribute to synaptic dysfunction that occurs early in AD.
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Alzheimer’s disease (AD) is the most common neurode-
generative disorder and has an increasing effect on our
ageing population. Pathological hallmarks of AD are
extracellular amyloid beta (Aβ) deposits and intracellu-
lar accumulation of hyper-phosphorylated tau protein
leading to the formation of neurofibrillary tangles (NFTs)
[1]. In addition, progressive synaptic dysfunction is
thought to occur in early stages of the disease and has
been found to correlate closely with cognitive deficits
observed in patients with AD [2-4]. There is emerging
evidence that the erythropoietin-producing hepatocel-
lular (Eph) receptors and their ligands, the so-called* Correspondence: a.rosenberger@vumc.nl
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article, unless otherwise stated.ephrins, are involved in aberrant synaptic functions
associated with cognitive impairment in AD [5]. Eph/
ephrin signaling is required for a wide range of bio-
logical processes both during embryogenesis and adult
life and involves the Eph receptors which form the lar-
gest of the 20 subfamilies of human receptor kinases.
Eph/ephrin signaling plays a role not only during synapse
formation and maturation and synaptic plasticity [6-8] in
the brain but also in directing cell positioning and migra-
tion, axon guidance [9,10], control of tissue morphogen-
esis, patterning, tumour invasion and metastasis, immune
function [11,12], haematopoiesis and blood clotting [13]
and tissue repair and maintenance.
Eph receptors and their ligands are exclusively membrane-
bound and hence cell-cell contact is required for activation
of the kinase through oligomerisation and transphosphor-
ylation [14]. EphA4 is the Eph receptor family member
that is most highly expressed in the adult hippocampus
where it plays a role in adult synaptic plasticity andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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synaptically expressed on dendritic spines of pyramidal
neurons and axon terminals [17]. Emerging evidence sup-
ports a critical role for EphA4/ephrin A3 signaling in the
regulation of spine morphology in the hippocampus. Acti-
vation of EphA4 upon binding to its glia-derived ligand
ephrin A3 was found to induce spine retraction and to
trigger the reduction of dendritic spines and synaptic pro-
teins, whereas inhibiting those interactions led to distorted
spine shape and organization in the murine hippocampus.
These findings suggest an essential role for EphA4 in the
elimination of excitatory synapses [18-20].
Two major forms of Aβ coexist in the brain: a shorter
form with 40 amino acid residues and a longer form
with 42 amino acids. The longer form is extremely toxic
and can self-aggregate to form oligomers (amyloid beta
oligomers, AβOs). Increased levels of EphA4 in cultured
neurons and synaptoneurosomes was reported to be cru-
cially involved in synaptic damage induced by AβOs [21].
Interestingly, reduced expression of the EphA4 receptor
has been linked to cognitive impairment in a transgenic
mouse model for AD overexpressing the human amyloid
beta precursor protein (APP) [22]. Loss of synapses is an
early event in AD pathogenesis. It has therefore been
suggested that changes in hippocampal EphA4 signaling
might precede the onset of memory decline in AD.
Whether EphA4 levels and activation are altered in
human AD brain is not known.
In the present study we are the first group to report
the involvement of EphA4 in AD pathology. We have
investigated EphA4 expression levels and localization
in human brain tissue of patients with AD and non-
demented controls. An association of EphA4 with the
hallmarks of AD was investigated using sequential sin-
gle stainings and double-labelling with phosphorylated
tau and amyloid beta.
Material and methods
Case selection
Human brain tissue was obtained from the Netherlands
Brain Bank (NBB, Amsterdam, The Netherlands). Prior
to death, all donors gave written informed consent ac-
cording to the Declaration of Helsinki for the use of
their brain tissue and medical records for research pur-
poses. This work was approved by the ethics committee
of the NBB. Dementia status at death was determined
on the basis of clinical information available during the
last year of life. Neuropathological diagnosis was per-
formed using histochemical analysis of formalin-fixed,
paraffin-embedded tissue from different parts of the brain,
including the frontal cortex (F2), temporal pole cortex,
parietal cortex (superior and inferior lobule), occipital
pole cortex and the hippocampus (essentially CA1 and
entorhinal area of the parahippocampal gyrus) withroutine stainings (hematoxilin and eosin, periodic acid
Schiff-Luxol fast blue). Hippocampus and cortical areas
were also stained with methenamine silver [23] and
using the Bodian staining. Immunohistochemistry was
performed using antibodies raised against hyperpho-
sphorylated tau (AT8) and Abeta. Staging of AD path-
ology was evaluated according to modified assessment of
Braak and Alafuzoff [24]. Cases with and without clinical
neurological disease diagnosis were processed identically.
Patients with co-morbidities like Parkinson’s disease or
Lewy-body disease were excluded from the study. Age,
sex, clinical diagnosis and Braak score for neurofibrillary
tangles (NFTs) of all cases used in study are listed in
Table 1. Post mortem delay of all cases was between 2 ½
and 9 hours. In total, 29 patients with AD and 19 controls
were included (see Table 1), with an average age at death
of 84 years (range 57 to 100 years old); of these, 22
(45.8%) were men.
Western Blotting
Frozen hippocampal tissue slides of patients in all Braak
stages (I-VI, n = 29) were cut and lysed with M-PER
(pH 7.6, Thermo Scientific) containing protease and
phosphatase inhibitors (Roche). After incubation for
30 min on ice and subsequent centrifugation (2 ×
10 min, 4°C, 15682 × g), protein concentrations of
the supernatants were determined with the standard
Bradford Lowry Assay (Bio-Rad Protein Assay).
Protein lysates were re-suspended in sample buffer
(Thermo Scientific) and heated for 5 minutes at 95°C.
Proteins were resolved by SDS-PAGE using 8–16% gradi-
ent polyacrylamide gels (mini-PROTEAN®TGX™, Bio-Rad)
in running buffer (25 mM Tris, 192 mM glycine, 0.1%
SDS, pH 8.3, Bio-Rad) and electrophoretically trans-
ferred onto a nitrocellulose membrane (0.2 μm; Whatman,
Protran™) in transfer buffer (25 mM Tris, 192 mM gly-
cine, 20% methanol, Bio-Rad). Membranes were blocked
for 1 hour in Tris-buffered saline (50 mM Tris pH 7.5,
0.15 M NaCl, 0.1% Tween-20) containing 5% BSA
(Roche Diagnostics) and incubated over night with pri-
mary anti-EphA4 antibody (1:500). A mouse monoclo-
nal antibody directed at the extracellular (c-terminal)
domain of the Ephrin-A4 receptor (amino acids 379–472;
BD Transduction Laboratories) and a rabbit polyclonal
EphA4 antibody directed at the intracellular domain
(amino acids 890–904; Abcam) were utilised. Incuba-
tion with a secondary antibody linked to horseradish
peroxidase ([HRP]-anti-rabbit IgG or HRP-anti-mouse
IgG, 1:1000, DAKO) for 1 hour followed. Immunoreac-
tive bands were detected with an enhanced chemilu-
minescence reagent (ECL Plus, GE Healthcare). Actin
(mouse anti-actin AC-40, Sigma) was used as a loading
control. The intensity of the resulting protein bands was
quantified using MacBiophotonics ImageJ (version 1.47 k).









1 CTRL 1 C M 77 07:30
2 CTRL 1 B F 77 02:55
3 CTRL 1 B F 83 04:05
4 CTRL 1 B F 85 07:05
5 CTRL 1 B M 80 03:18
6 CTRL 1 0 F 81 04:25
7 CTRL 2 0 F 87 05:05
8 CTRL 2 0 F 76 05:45
9 CTRL 2 0 F 93 05:50
10 CTRL 2 B F 89 06:25
11 CTRL 2 B M 79 09:00
12 CTRL 2 0 M 81 07:55
13 CTRL 3 C F 89 15:40
14 AD 3 B M 84 05:20
15 AD 3 A F 98 06:05
16 AD 3 B F 96 04:00
17 AD 3 C M 78 05:10
18 AD 3 C F 82 06:05
19 AD 4 C F 84 04:50
20 AD 4 C M 88 05:00
21 AD 4 C F 87 06:40
22 AD 4 C F 100 05:15
23 AD 4 C M 77 05:00
24 AD 5 C F 84 04:30
25 AD 5 C F 77 03:45
26 AD 5 C F 78 08:25
27 AD 5 C M 77 05:39
28 AD 5 C M 86 06:15
29 AD 5 B M 69 07:10
30 AD 6 C M 62 06:45
31 AD 6 C F 66 05:20
32 AD 6 C F 62 -
33 AD 6 C M 57 07:40
34 AD 6 C F 84 04:50
35 AD 6 C M 65 06:00
Double stainings
36 AD 4 C F 93 02:30
37 AD 5 C M 93 04:30
38 AD 5 C F 81 -
39 AD 6 C M 74 05:35
40 CTRL 1 0 M 96 06:30
41 CTRL 1 A F 94 04:05
Table 1 Cases used in this study (Continued)
42 CTRL 2 A M 88 04:43
43 CTRL 1 B F 77 02:55
Additional frozen tissue lysates
44 AD 4 C M 84 03:40
45 AD 4 C M 81 04:50
46 AD 6 C M 57 03:50
47 CTRL 1 0 M 58 05:15
48 CTRL 1 B F 83 05:30
CTRL, control case; AD, Alzheimer’s disease case; PMD, post mortem delay; F,
female; M, male.
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Actin) of the individual samples (Figure 1). Statistical ana-
lyses were performed by t-test analysis for independent
samples using GraphPad Prism version 6.0 (San Diego,
CA). Furthermore, whole protein extracts were analysed
by Immuno-blot analysis with SDS-PAGE using pre-
cast stainfree gradient gels (Bio-Rad; Additional file 1:
Figure S6). After UV activation of the gel, proteins were
visualised and relative protein amounts were determined
and used for normalization. Recombinant proteins EphA1
(75 kDa, aa 569–976; Pro Quinase), EphA4 (72 kDa, aa
586–986; Carna Biosciences) and EphB2 (73 kDa, aa 581–
987; Carna Biosciences) were used to proof specificity of
the rabbit polyclonal EphA4 antibody. The EphA4 mouse
antibody binds extracellularly (aa 379–472) which is
outside of the binding domain for recombinant EphA4,
therefore only the polyclonal rabbit antibody is shown
(Additional file 2: Figure S8).
Immunohistochemistry
For single immunohistochemical analysis, formalin fixed
(4%, 24 hours) paraffin embedded 5 μm thick sequential
sections were mounted on coated glass slides (Menzel
Gläser Superfrost PLUS, Thermo Scientific, Braunschweig
Germany), dried over night at 37°C and deparaffinised. In
order to block the endogenous peroxidase, the sections
were incubated in 0.3% (v/v) H2O2 in methanol (100%) for
30 min at RT. Sections were boiled in 10 mM sodium cit-
rate buffer (pH 6.0) for 10 minutes for antigen retrieval.
They were incubated over night with the primary antibody
at room temperature. Mouse monoclonal anti-EphA4
[25-27] (1:200, BD Transduction Laboratories™); mouse
monoclonal anti-phospho-tau [28] (AT8 1:200, Pierce
Biotechnology, Rockford IL, USA); mouse monoclonal
anti-Aβ (IC16 1:500, Prof. C. Korth, Heinrich Heine
University Düsseldorf, Germany) and mouse monoclo-
nal anti-Aβ 1–17 (VU17 [29] 1:1000, Dr. R. Veerhuis,
VU University Medical Center, Amsterdam, NL) were
used. As a second step, envision mouse/rabbit HRP
(DAKO) was used. Sections were stained using the En-
Vision method (incubation with Dako REAL™ EnVison™
Figure 1 Detection of EphA4 immunoreactivity in hippocampal brain tissue lysates of AD and non-demented controls. Western blot
analysis of Alzheimer’s disease (AD) and control (CON) cases for EphA4 with rabbit polyclonal antibody (aa 890–904, intracellular domain).
B) Relative signal intensities (EphA4/Actin) of single cases per Braak stage (error bars indicate standard deviation) C) Western blot analysis for
EphA4 mouse monoclonal antibody (aa 379–472, extracellular domain). D) Mean relative signal intensities with standard deviation.
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colour was developed using 3,3-diaminobenzidine (EV-
DAB; DAKO) as chromogen. Sections were counterstained
with hematoxylin and mounted using Quick-D mount-
ing medium (Klinipath B.V., Duiven, The Netherlands)
(Figures 2 and 3). Between all incubation steps, sections
were washed extensively with phosphate buffered saline
(PBS, pH 7.4), which also served as a negative control
by omission of primary antibodies.
Double immunohistochemistry: EphA4 with either Aβ
or pTau
To determine the co-localization of EphA4 with amyl-
oid beta and phosphorylated tau double immunohisto-
chemistry was performed. Hippocampal brain slices were
pre-incubated with serum-free protein blocking (SFPB,
DAKO) for 10 min and subsequently incubated with
mouse monoclonal anti-EphA4 [25-27] (1:200, IgG1, BD
Transduction Laboratories™) for 1 hour. After washing
with PBS, slices were incubated with EnVision solution
(goat anti-rabbit HRP, undiluted, DAKO) for 30 minutes.Colour was developed using DAB as chromogen. Sections
were treated with 10 mM sodium citrate buffer pH 6.0
heated at 180 Watt for 10 minutes. After pre-incubation
with SFPB for 10 minutes, sections were incubated with
anti-Aβ VU 1–17 antibody [29] (1:1000, IgG2a, VU medical
center) or anti-pTau AT8 antibody (dilution 1:200, IgG1)
for 1 hour. Sections were washed with PBS and incubated
with either GαMIgG2aHRP (dilution 1:100, Southern
Biotech) for the detection of VU 1–17 or GαMIgG1AF
(dilution 1:100, Southern Biotech) for the detection of
AT8 for 1 hour at RT. Colour was developed using Liquid
Permanent Red (LPR, DAKO) as chromogen. Slices were
counterstained with hematoxylin and mounted using
Aquamount (BDH Laboratories Supplies). The Nuance™
spectral imaging system (CRi, Woburn, MA) was used
for the analysis of double stained specimens. Spectral
imaging data cubes were taken from 460–660 nm at
10 nm intervals and analyzed with the Nuance™ software.
Spectral libraries of single-brown (DAB), single-red (LPR)
and hematoxylin were obtained from control slides. The
resulting library was applied to the double stained slides
Figure 2 (See legend on next page.)
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Figure 2 Detection of EphA4 immunoreactivity in non-demented controls and AD hippocampus. Immunohistochemical detection of
EphA4 (DAB i.e. brown colour) in the CA1 region of A) non-demented control (Braak 2 O, #7 in Table 1) and B) AD (Braak 6 C, case #32 in Table 1)
and with 2x higher magnification C) and D) respectively. EphA4 immunoreactivity in the dentate gyrus (DG) and stratum lacunosum (SL) in
E) control (Braak 1 B, #5 in Table 1) and F) AD (Braak 6 C, #30 in Table 1) with 2x higher magnification in G) and H) respectively. Inserts in E) and
F) are 2x higher magnifications of neurons of the granular layer (GL). The first panel A-D shows the CA1 region, whereas the second panel E-H
are images from the CA4 and granular layer. All sections were counterstained with hematoxylin. Scale bar 100 μm for A + B, E + F and 50 μm for
C + D, G + H.
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unmixed into individual black-and-white images, repre-
senting the localization of each of the reaction products,
and reverted to fluorescence-like images composed of
pseudo-colours using the Nuance™ software (Figure 4).
Analysis and quantification of EphA4 immunostaining
Presence of EphA4 in hippocampal subregions CA1
and subiculum were analysed in sections immuno-
stained with EphA4 (BD Transduction Laboratories)
by an observer blinded to the clinical and pathological
diagnosis. Microscopic fields (n = 4, magnification 100x)Figure 3 Detection of EphA4, Aβ and pTau in consecutive brain slide
(DAB i.e. brown colour), B) Aβ and C) pTau in the dentate gyrus (DG) and
case #30 in Table 1) indicated with the vessel in the right lower corner. Arr
shown for EphA4, Aβ and pTau in D), E) and F) respectively in consequent
Table 1). All sections were counterstained with hematoxylin. Scale bar 100were analysed (Table 2). The number of EphA4 deposi-
tions was scored as follows: 0, none; 1, one to ten de-
positions; 2, eleven to twenty depositions; 3, more than
twenty. The presence of Aβ plaques (plaque severity)
was quantified in a similar manner (0, none; 1, occasional
plaque; 2, several plaques scattered throughout the field; 3,
abundant presence of plaques). The presence of pTau-
tangles was scored: 0, none; 1, mild (occasional immuno-
reactivity); 2, moderate (scattered throughout the field); 3,
severe (abundant presence of plaques). Additional file 3:
Figure S7 shows examples for scoring of EphA4, Aβ and
pTau immunoreactivity.s of AD hippocampus. Immunohistochemical detection of A) EphA4
stratum lacunosum (SL) of consecutive brain slides in AD (Braak 6 C,
ows are pointing out the same plaques. A 2x higher magnification is
brain slides for a different patients with AD (Braak 6 C, case #31 in
μm for A-C and 50 μm for D-F.
Figure 4 Double-stainings of EphA4 with Aβ and pTau. Double-stainings of EphA4 (DAB i.e. brown colour) with A) pTau (AT8, LPR i.e. pink
colour) in a hippocampal area of a patient with severe AD (Braak 6, #39 in Table 1) and B) Aβ (VU-17, LPR i.e. pink colour). Spectral images on the
right side (Aβ or pTau in red; EphA4 in green; nuclei in blue). Sections were counterstained with hematoxylin. Scale bar is 50 μm.
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Pairwise correlation analyses for non-parametric or-
dinal data were conducted using IBM SPSS Statistics
22.0 (Figure 5A-D). Spearman’s correlation coefficients
and Kendall’s tau coefficients were calculated. Correlations
were considered significant in the 95% confidence interval
when p < 0.05 (Table 3).Results
In the present study we report on the involvement of
EphA4 in human AD pathology. We determined the
levels of EphA4 in hippocampal brain tissue of AD and
non-demented control patients and found an association
with the two hallmarks of AD (pTau and Abeta) using
immunohistochemical analysis.Expression levels of EphA4 in the human hippocampus at
different stages of AD
In order to investigate protein levels of EphA4 we ana-
lysed frozen hippocampal brain tissue lysates of AD pa-
tients (n = 18) and non-demented controls (n = 11) by
Western Blotting. Using two different EphA4 antibodies
i.e. a rabbit polyclonal antibody raised against the intra-
cellular part of the EphA4 and a mouse monoclonal
antibody to detect the extracellular domain of EphA4.
The rabbit antibody detected a protein (fragment) of
approx. 108 kDa whereas the mouse antibody showed a
band that correlates to a molecular weight of 130 kDa
(Figure 1 A,C). Actin was used as a loading control (mo-
lecular weight is ~ 45 kDa) and to determine relative
signal intensities for EphA4 (Figure 1B,D). We observed
no significant difference in the levels of the intracellular
Table 2 Scoring of EphA4, Aβ plaques, pTau plaques and pTau tangles
Case no. Braak Braak (amyloid) EPHA4 plaques pTau plaques pTau tangles Aβ plaques
1 1 C + ++ + ++
2 1 B 0 0 0 +++
3 1 B + 0 + +++
4 1 B + 0 0 +
5 1 B 0 0 + ++
6 1 0 0 0 0 0
7 2 0 + 0 ++ 0
8 2 0 0 0 +++ 0
9 2 0 +++ 0 0 0
10 2 B + +++ + +++
11 2 B ++ + ++ ++
12 2 0 + 0 ++ +
13 3 C +++ +++ +++ +++
14 3 B 0 + + +++
15 3 A + 0 ++ +
16 3 B + ++ ++ +
17 3 C + ++ +++ +++
18 3 C + 0 + +++
19 4 C +++ ++ +++ +++
20 4 C + +++ ++ ++
21 4 C ++ 0 ++ +++
22 4 C + + +++ +++
23 4 C +++ + +++ +++
24 5 C +++ ++ +++ +++
25 5 C +++ +++ +++ ++
26 5 C +++ +++ ++ +++
27 5 C + +++ ++ +++
28 5 C + 0 +++ +++
29 5 B +++ +++ + +++
30 6 C +++ +++ +++ +++
31 6 C +++ + +++ +++
32 6 C +++ ++ +++ +++
33 6 C 0 +++ +++ +++
34 6 C +++ +++ +++ +++
35 6 C + +++ ++ +++
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and controls (Figure 1). We analysed the levels of EphA4
at different stages of AD and found no significant differ-
ences (results not shown). Since EphA4 is an integral
membrane protein we analysed whole tissue lysates (con-
taining soluble and insoluble fraction). No difference in
average levels was observed between AD and control
hippocampus (see Additional file 1: Figure S6). In conclu-
sion we observed no differences in EphA4 levels in hippo-
campal tissue at different stages of AD. Recombinantproteins EphA1, EphA4 and EphB2 were used to prove
specificity of the rabbit polyclonal EphA4 antibody. The
mouse anti-EphA4 antibody detects EphA4 at aa 379–
472. This sequence is not present in recombinant
EphA4 which represents a shorter fragment of EphA4.
Therefore mouse anti-EphA4 antibody is not able to de-
tect recombinant EphA4 (Additional file 2: Figure S8).
No bands were observed for recombinant EphA1 and
EphB2 whereas a band for recombinant EphA4 was de-
tected at 72 kDa for all three concentrations (1:50,
Figure 5 Pairwise correlation analysis of EphA4, pTau plaques and tangles and Aβ plaques. Correlation of EphA4 deposits with A) pTau
tangles, B) pTau plaques and C) Abeta plaques. D) Distribution of EphA4 deposits over Braak stages (I-VI). E) Table with the corresponding
correlation coefficients (Spearman’s rho and Kendall’s tau) as well as p-values. Correlations are considered significant when p < .05.
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the rabbit EphA4 antibody.
EphA4 localization in patients with Alzheimer’s disease
Since we observed no difference in the levels of EphA4
we wondered whether the localisation of EphA4 mightTable 3 Correlation coefficients for pairwise comparisons of E
(according to Figure 5)
Kendall’s tau [τ]
A EphA4/pTau tangles .393, p = .007*
B EphA4/pTau plaques .329, p = .025*
C EphA4/Abeta plaques .259, p = .084
D EphA4/Braak stage .421, p = .003*change in AD versus non-demented controls. The
mouse monoclonal antibody directed at the extracellu-
lar (c-terminal) domain of EphA4 was used for detec-
tion of the protein. In non-demented control cases
(without AD pathology), a low intense immune-reactive
signal of EphA4 was detected in the parenchyma. ThephA4 with the hallmarks of AD and Braak stage
Spearman’s rho [rs] significance [p < .05]
.420, p = .011* significant
.378, p = .023* significant
.282, p = −096 not significant
.486, p = .003* significant
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pus (Figure 2A,C). In contrast, in AD cases EphA4
immuno-reactivity was observed in plaque-like structures
(Figure 2B,D). Interestingly, EphA4 immuno staining of
these plaque-like structures was observed more frequently
in the higher Braak stages (V and VI), but some of the
samples representing low stages (three in Braak I and 5 in
Braak II) showed the same pattern. The EphA4-positive
plaque-like structures showed considerable variations in
shape and size (5–50 μm) and were detected in all sub-
regions of the hippocampus.
Intense EphA4 immunostaining was observed in the
cytoplasm of granular neurons in the dentate gyrus of
AD but not in the dentate gyrus of non-demented control
cases (Figure 2E,F). In non-demented controls, EphA4 im-
munoreactivity was found as a fine punctate line in the
plexiform layers of the dentate gyrus (Figure 2G). In AD
patients, EphA4-positivity was frequently decorating
the dentate gyrus showing a brown band in the perfor-
ant path target zone of the outer molecular layer of the
dentate gyrus, forming a frame around the granular
layer (Figure 2F,H). This staining pattern was not ob-
served in control cases. EphA4-positivity was not re-
stricted to specific subareas of the hippocampus but
was also found in and around neurons of the granular
layer and in the stratum lacunosum. The presence of
EphA4 immunoreactive plaque-like deposits in the CA
regions of the hippocampus and entorhinal cortex in
combination with the intense EphA4 immunostaining
of the molecular layer was most prominent in demented
individuals. Interestingly, EphA4 immunoreactive plaques
were also observed in the hippocampi of non-demented
controls (Braak II, see scoring Table 2) which points to-
wards an early involvement of EphA4 in AD pathology.
EphA4 partially co-localizes with pTau and neuritic Aβ
plaques
The detection of EphA4 immunoreactivity plaque-like
structures suggests a co-localization with neuritic pla-
ques. In order to investigate the co-occurrence of EphA4
with neuritic plaques, adjacent brain tissue sections were
stained for EphA4, pTau and Aβ (Figure 3). Consecutive
brain slices were stained for Aβ, pTau and EphA4 and
partial co-localization in the hippocampus of AD pa-
tients was revealed.
In order to corroborate the possible co-localization of
EphA4 with either Aβ or pTau, double-immunostaining was
performed. We found confirmation of partial co-localization
of EphA4 with pTau and Aβ-immunoreactive plaques in
AD patients (Figure 4A). EphA4-immunoreactivity was
characteristically found at the ends of dystrophic neur-
ites around central Aβ plaques (Figure 4B). EphA4 im-
munoreactivity is less intense compared to that of Aβ or
pTau which could reflect differences in the antigenbinding properties of the different antibodies. So EphA4
localization is clearly linked to the deposition of both
Aβ and pTau.EphA4 depositions in the hippocampus of AD patients at
different Braak stages
In order to investigate whether the number of EphA4
depositions increases with Braak stage and correlates
with the hallmarks of AD, immunoreactivity for EphA4
was analysed in a new second cohort representing all
Braak stages (I-VI) (Table 2). Adjacent tissue sections were
stained and scored for EphA4 depositions, Aβ plaques,
pTau-positive plaques and pTau tangles (see Additional
file 3: Figure S7 for scoring example).
To examine the relationship between EphA4 and the
hallmarks of AD, Spearman’s correlation [rs] and Kendall’s
correlation [τ] analyses for non-parametric ordinal data
were performed (Table 3). Spearman’s correlation coeffi-
cients are used for correlation analyses of non-parametric
data sets. Kendall’s correlation coefficients are preferred
for small sample sizes with a large number of tied ranks.
The analyses revealed a significant correlation between
EphA4 positive depositions and pTau-positive tangles
(Figure 5A; rs = .420, p < .05; τ = .393, p < .05) and between
EphA4 and pTau-positive plaques (Figure 5B; rs = .378,
p < .05; τ = −.329, p < .05). No significant correlation was
found between EphA4-load and Aβ plaques (Figure 5C;
rs = .282, ns; τ = .259, ns). However, the correlation between
EphA4 deposits and Braak stage was evident (Figure 5D;
rs = .486, p < .05; τ = .421, p < .05). Table 3 summarizes the
obtained correlation coefficients and p-values.Discussion
Synaptic loss is one of the major pathological hallmarks
of AD. This is considered to be an early event in the
pathogenesis of the disease. Synaptic failure correlates
with cognitive decline and is observed in patients with
mild cognitive impairment (MCI) and incipient AD [3].
The molecular mechanism of synaptic dysfunction in
AD remains elusive.
The tyrosine kinase receptor EphA4 is essential for
synaptic function as it is involved in dendritic spine
morphogenesis, synapse formation and maturation [5].
EphA4 is highly expressed in the adult hippocampus,
where it is known to play a role in adult synaptic plasticity
and learning [16,30]. Of all cortical areas, the hippocam-
pus appears to be most severely affected by the loss of syn-
aptic proteins in AD (44 to 55%) [31]. Interestingly,
analysis of synaptoneurosomes from AD patients revealed
a ~2-fold increase in EphA4 mRNA [32], suggesting a role
in synaptotoxicity for EphA4 Therefore we investigated
EphA4 expression and localization in the hippocampus of
patients at various Braak stages.
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http://www.actaneurocomms.org/content/2/1/79In this study the total EphA4 protein levels were simi-
lar in AD patients compared to control cases. However,
immunohistochemical localization of EphA4 revealed an
altered distribution in AD compared to control hippo-
campus. EphA4 partially co-localized with neuritic amyl-
oid beta plaques. An aberrant function of EphA4 might
be the underlying cause for the altered distribution of
EphA4 in different Braak stages. Thus, EphA4 could be
contributing to synaptic dysfunction which is considered
an early event in AD.
So far, reports about changes in EphA4 protein levels
in AD hippocampus have been contradictory. Simón
et al. reported a reduction of EphA4 (20%) in hippocam-
pal tissue of three patients with very mild cognitive defi-
cits (Braak stage II and III) compared to three control
subjects [33]. Matsui et al. showed that total protein
levels of EphA4 in AD brains were not altered compared
to controls. Furthermore they reported a decrease of
membrane associated EphA4 (intracellular domain) in
frontal lobes of AD cases while the amount of full-
length EphA4 was unchanged [34]. In the present study
we investigated a large cohort (n = 35) covering all Braak
stages using two different antibodies directed at different
epitopes of EphA4. EphA4 fragments with different mo-
lecular weights (108 kDa vs. 130 kDa) were detected.
This discrepancy can be explained by the different bind-
ing sites of the used antibodies. Overall, we were not
able to detect changes in EphA4 protein levels between
control and AD groups and between different Braak
stages when we used Western Blot analysis.
In contrast, at the immunohistochemical level we ob-
served differences in the staining patterns of EphA4
when comparing control and AD cases. We showed that
depositions of the EphA4 protein kinase are present in
all subareas of the hippocampus in AD patients. The
number of EphA4 deposits increases with Braak stage
and those deposits partially co-localize with neuritic
plaques and tangles. Moreover, EphA4 immunoreactive
plaques are already present in Braak stage II which
points towards an involvement of EphA4 in the early
stages of AD pathology. The increased occurrence of
EphA4 deposits with AD pathology in the absence of
changes in total EphA4 protein levels indicate an altered
distribution of EphA4. The important role of EphA4 in
synaptic dysfunction, an early event in AD, has been re-
ported [35]. Pathological changes happen in the brain
even decades before the first clinical symptoms emerge.
Therefore, it is likely that the aberrant EphA4 staining
in part of the control cases (Braak stage II and III) poses
an early event in AD pathogenesis and is therefore
specific.
Mostly, investigations into AD related synaptic changes
have focused on the toxic effects of Aβ. Like the amyl-
oid precursor protein (APP), EphA4 is a substrate of γ-secretase [34]. The EphA4 intracellular domain (EICD)
that remains after cleavage is known to enhance the
formation of dendritic spines via activation of the Rac
signaling pathway [34]. It has been suggested that aber-
rant γ-secretase activity followed by hindered cleavage
of EphA4 results in reduced formation of dendritic
spines and may be the major cause of synaptic failure in
AD [36]. In addition, reduced EphA4 levels have been re-
ported in whole-cell lysates of hAβPPswe-ind mice and
Tg2576 mice compared to non-transgenic mice [33].
Those hAβPPswe-ind mice show amyloid-related pathology
but no accumulation of pTau in tangles. These data
strengthen the possible link between Aβ and aberrant
EphA4 signaling.
The emerging view is that toxic amyloid-β oligomers
(AβOs) are an important pathological factor in early neu-
rodegenerative events in AD [37]. Two major forms of Aβ
coexist in the brain: a shorter form with 40 amino acid
residues and a longer form with 42 amino acids. The lon-
ger form is extremely toxic and can self-aggregate to form
oligomers (amyloid beta oligomers, AβOs) [2]. Those olig-
omers accumulate into Aβ deposits in patients with AD. It
has been reported recently that activation of the Abelson
non-receptor tyrosine kinase c-Abl, a kinase downstream
of EphA4, mediates synaptic loss and long term potenti-
ation in dendritic spines of cultured rat hippocampal neu-
rons. The co-localization of c-Abl with amyloid plaques,
neurofibrillary tangles and granulovacuolar degeneration
in the hippocamups and entorhinal cortex of AD patients
has been reported in 2009 by Jing et al. [38]. AβOs activate
the c-Abl kinase and thereby induce synaptic loss [21].
Concomitantly, EphA4 tyrosine phosphorylation is in-
creased in these cultured neurons and in synaptoneuro-
somes exposed to AβOs. EphA4/c-Abl activation is a
key-signaling event mediating the synaptic damage in-
duced by AβOs. EphA4/c-Abl signaling could hence be
a relevant pathway involved in the early cognitive de-
cline observed in AD patients [21].
In human brain, a stronger relation between EphA4
and pTau positive plaques exists. In AD, c-Abl is detected
in neurofibrillary tangles [38] and phosphorylates tau dir-
ectly [39] and through activation of Cdk5 [40]. In the
present study, we show a significant correlation between
EphA4 positive depositions and pTau-positive plaques and
an almost significant correlation with pTau-positive tan-
gles in AD. Also Matsui et al. previously reported a correl-
ation between the intracellular domain of EphA4 (EICD)
and tau phosphorylation, although the correlation did not
reach statistical significance. In contrast, the level of EICD
did not correlate with the level of Aβ [34].
Tau may be involved in synaptic dysfunction in de-
mentia [36], strengthening the association with EphA4
[5]. A key question remains whether the association with
EphA4 is causally related to tau phosphorylation and
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phosphorylation of tau contributing to the formation of
neurofibrillary tangles and neuronal dystrophy, or on the
contrary, aggregating tau affects the subcellular distribu-
tion of key proteins involved in synaptic function such as
the EphA4 receptor. So far several groups have reported
that Eph/ephrin signaling up-regulates tau expression and
phosphorylation [41,35]. When EphA4 is activated by
ephrin A1 it recruits and phosphorylates cyclin-dependent
kinase 5 (CDK5) [35]. CDK5 is a tau kinase and is in-
creased in AD brain [42]. Increased CDK5 immunoreac-
tivity is observed in pretangle neurons supporting its
involvement in early stages of AD pathogenesis [43].
The significance of a dysregulation of CDK5 by EphA4
in pathological conditions remains elusive.
In our study, EphA4 depositions partially co-localize
(~30%) with neuritic Aβ plaques in human hippocampal
brain tissue. Manczak et al. recently reported a physical
interaction between Aβ and phosphorylated Tau [44].
They found an abnormal interaction of oligomeric Aβ
with pTau in neurons of post mortem brains from AD
patients. This interaction may be involved in neuronal
and synaptic damage, leading to cognitive decline in
incipient AD patients [44]. Those findings may explain
that EphA4 is related to both Aβ and pTau and suggests
an underlying common pathway. Further studies are
necessary to shine light on the relation of those proteins
and the significance in the progression of AD.
Four recent large late-onset AD (LOAD) genome-wide
association studies (GWAS) have identified EPHA1 as a
genetic factor. Like EphA4, EphA1 is suggested to be
important for synaptic function [12,45]. This supports
the emerging evidence that the Eph receptors and their
ligands, the ephrins, are involved in aberrant synaptic
functions associated with cognitive impairment in AD
[5]. In this study we show that EphA4 co-localizes with
neuritic plaques in human brain tissue of patients with
AD. EphA4 is associated with both Aβ and pTau. The
altered distribution of EphA4 in AD hippocampus may
reflect a decreased function of EphA4, which is likely to
contribute to synaptic dysfunction that occurs in the early
stages of AD. Pathological changes happen decades before
the first clinical symptoms emerge explaining EphA4-
positivity in early Braak stages (II and III, see Table 2).Additional files
Additional file 1: Figure S6. Example of EphA4 detection in whole
tissue lysates by Western blot analysis. A) Western blots with whole tissue
lysates of hippocampi of all Braak stages (0-VI). B) Box blot analysis of
Western Blots for EphA4. Signal intensity for Braak 0-III and Braak IV-VI.
Specificity p < 0.05.
Additional file 2: Figure S8. Western Blot analysis of specificity of
EphA4 (rabbit) antibody against recombinant EphA1 and EphB2. Therabbit polyclonal EphA4 antibody is specific for EphA4 (band at 72 kDa).
No bands are observed for recombinant EphA1 and EphB2.
Additional file 3: Figure S7. Example of scoring for quantification of
EphA4, pTau and Aβ. For explanation of scoring see material and
methods and Table 2.
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